Clinical Report: ASCRS 2026 Highlights Performance of TECNIS PureSee EDOF IOL
Overview
New data presented at ASCRS 2026 demonstrate the TECNIS PureSee EDOF IOL's strong performance in distance and intermediate vision, with high patient satisfaction and low rates of visual disturbances. The findings are supported by both a randomized clinical trial and a large post-market observational study.
Background
The TECNIS PureSee intraocular lens (IOL) represents a significant advancement in cataract surgery, aiming to enhance visual range while maintaining contrast sensitivity. With FDA approval, this purely refractive extended depth of focus (EDOF) lens is designed to improve patient outcomes by reducing dependence on spectacles. Understanding its clinical performance is crucial for optimizing cataract surgery results.
Data Highlights
| Study Type | Key Findings |
|---|---|
| Randomized Trial | Distance-corrected intermediate vision: 20/28 (monocular); 94% maintained 20/25 or better visual acuity. |
| Post-Market Study | Mean binocular uncorrected distance vision: 20/19; 96% spectacle independence for distance. |
Key Findings
- TECNIS PureSee IOL shows strong distance vision and improved intermediate performance compared to monofocal control.
- Patients gained approximately 1.5 lines of near vision versus control.
- Visual disturbance rates were reported as low, with performance independent of pupil size.
- High patient satisfaction, with over 90% reporting little or no need for distance spectacles.
- In a post-market study, 95% of patients reported independence from spectacles for intermediate vision.
Clinical Implications
The TECNIS PureSee IOL offers a promising option for cataract surgery, providing enhanced visual outcomes and high rates of spectacle independence. Clinicians should consider this lens for patients seeking improved intermediate vision and reduced reliance on corrective eyewear.
Conclusion
The findings from ASCRS 2026 reinforce the TECNIS PureSee IOL's efficacy as a leading choice in EDOF lenses, highlighting its potential to improve patient satisfaction and visual performance in cataract surgery.
Related Resources & Content
- Ophthalmology Management, 2025 -- Purely Refractive EDOF IOL Reduces Spectacle Dependence
- Glaucoma Physician, 2026 -- FDA Approves Tecnis PureSee IOL
- The Ophthalmologist, 2025 -- Enhanced Visual Clarity with Reduced Complications: An Updated Assessment of EDOF Lens Efficacy
- Ophthalmology Management, 2026 -- Tecnis PureSee IOL Wins FDA Approval
- FDA Summary of Safety and Effectiveness (SSED) Template
- The Ophthalmologist — Enhanced Visual Clarity with Reduced Complications: An Updated Assessment of EDOF Lens Efficacy
- Summary of Safety and Effectiveness (SSED) Template
- https://www.escrs.org/media/ooama3sf/full-extended-guideline-24092025.pdf
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
